메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases

SAN FRANCISCO, Dec. 16, 2025 -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical study (NCT06764940) of Utidelone Injection(UTD1) combined with capecitabine for the treatment of HER2-negative breast cancer brain metastases (BCBM). The study adopts a two-stage design and plans to enroll approximately 120 subjects. The primary endpoint is the central nervous system objective response rate (CN
- 김갑성 기자
- 2025-12-16 12:55
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development

The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics SHANGHAI, Dec. 16, 2025 -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developi
- 김갑성 기자
- 2025-12-16 08:30
Perennial Healthcare City Launched Adjacent to Chongqing East HSR Station, Western China's Largest HSR Hub

Establishment of new healthcare gateway in Chongqing amid the 10th anniversary of the Chongqing Connectivity Initiative and as part of the 35th anniversary celebration of Singapore-China diplomatic relations; Maiden investment in Chongqing marks Perennial Holdings' sixth healthcare-centric TOD, further strengthening its footprint in China SINGAPORE, Dec. 16, 2025 -- Perennial Holdings Private Limited ("Perennial Holdings") yesterday launched Perennial Healthcare City, adjacent to the Chongqing East High-Speed Railway ("HSR") Station ("Perennial
- 황정호 기자
- 2025-12-16 07:05
Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD

HANGZHOU, China, Dec. 16, 2025 -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human clinical study at The Second Affiliated Hospital, School of Medicine, Zhejiang University ("SAHZU"). This milestone marks the first clinical evaluation of the device's safety and performance in patients. PVAD supports the cardiac output via a percutaneously implanted pump, reduces the l
- 김갑성 기자
- 2025-12-16 06:00
Miroma Project Factory: Powers Clinical-Grade App for One of Australia's Largest Smoking Cessation Trials

SYDNEY, Dec. 16, 2025 -- Miroma Project Factory (MPF) has delivered a bespoke mobile solution for Screen2Quit, part of the International Lung Study trial and one of Australia's most ambitious research studies targeting smoking cessation in people undergoing lung cancer screening. Commissioned by the Thoracic Research Centre at the University of Queensland and developed in partnership with Queensland Health, Screen2Quit is a revised, clinical version of the My QuitBuddy application redeveloped and instrumented to collect participant backend data for a multi-year randomised contr
- 김갑성 기자
- 2025-12-16 05:07
HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)

CHENGDU, China, Dec. 15, 2025 -- HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), announced it has officially submitted its commitment letter to the Science Based Targets initiative (SBTi). HitGen has pledged to set near-term science-based targets within the next two years, aligned with the SBTi's stringent criteria. This commitment entails the future development and implementation of a series of emission reduction measures designed to cut the company's greenhouse gas emissions across its value chain to a level consistent with the 1.5°C temperature goal
- 김갑성 기자
- 2025-12-15 22:30
PM-International expands child sponsorships to 8,000 with €2.88 million donation

SCHENGEN, Luxembourg, Dec. 15, 2025 -- Global support for children in need is declining rapidly. According to World Vision, governments and institutions worldwide have cut funding for children's aid by $16.3 billion, limiting access to food, healthcare and education for millions of vulnerable children. At the same time, PM-International is expanding its commitment through its charity Foundation PM We Care. In 2026, it will increase the commitment to the partnership with World Vision by supporting an additional 1,400 children, raising the total number of sponsored children to 8,0
- 김갑성 기자
- 2025-12-15 22:13
NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE

NEW YORK, Dec. 15, 2025 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on December 15th Stocks are fractionally higher early Monday as a busy week of economic data begins, with non-farm payrolls and retail sales Tuesday, and November CPI Thursday. Seven of the ten largest IPOs of 2025 debuted on the NYSE, including Circle, Figma, and Klarna. NYSE President Lynn Martin said the 2026
- 황정호 기자
- 2025-12-15 22:10
Neurabody Enters the UK Market with Selfridges Launch, Showcasing the Future of AI-Driven Ergonomics

LONDON, Dec. 15, 2025 -- Neurabody, the AI-driven posture science company transforming modern ergonomics, today announced its official launch at Selfridges London, marking a significant milestone in the company's global expansion and consumer entry into the UK market. With this debut, Selfridges customers will experience NeuraSit, Neurabody's intelligent posture-support system that merges ergonomic engineering, embedded sensors, and real-time AI feedback to help users improve posture effortlessly. The product will be featured within Selfridges' curated mix of forward-thinking t
- 김갑성 기자
- 2025-12-15 22:00
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research

Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced a collaboration with Daiichi Sankyo (TSE: 4568) that aims to accelerate biomarker discovery and optimize translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programs. Da
- 김갑성 기자
- 2025-12-15 22:00

이전

51 52 53 54 55 56 57 58 59 60

많이 본 기사

최근기사

2026-03-03_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 10시 40분